NCT00462982

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma.

Detailed description

OBJECTIVES: Primary * Determine the efficacy of sunitinib malate, in terms of objective radiographic response of brain lesions, in patients with brain metastases secondary to renal cell carcinoma or melanoma. Secondary * Determine overall and progression-free survival. OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed periodically.

Conditions

• Kidney Cancer
• Melanoma (Skin)
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	sunitinib malate

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2007-04-19
• Last updated: 2015-12-30
• Results posted: 2015-12-30

Locations

1 site across 1 country: United States